Stay updated on Phase II Anti-PD1 Epigenetic Therapy Clinical Trial
Sign up to get notified when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.

Latest updates to the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a site version update with no changes to study data or participant information.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.4.2; removed Revision: v3.4.1 and the lapse in government funding notice.SummaryDifference0.4%

- Check41 days agoChange DetectedAdded a government funding lapse notice and a status update for the NIH Clinical Center; introduced revision tag v3.4.1 and removed v3.4.0.SummaryDifference0.4%

- Check48 days agoChange DetectedThe page now displays a glossary option and updates the footer with QC-related metadata (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check62 days agoChange DetectedMinor site version update from Revision: v3.3.3 to v3.3.4; this change does not affect the study details or user-facing content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedAdded a unified Locations section with site entries for California, District of Columbia, Maryland, and Pennsylvania. Removed the California Locations, District of Columbia Locations, Maryland Locations, Pennsylvania Locations subpages and the HHS Vulnerability Disclosure link.SummaryDifference0.5%

Stay in the know with updates to Phase II Anti-PD1 Epigenetic Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Anti-PD1 Epigenetic Therapy Clinical Trial page.